Category: Wörwag Pharma GmbH & Co. KG

Diabetic Polyneuropathy – What’s new in multimodal management?

Wörwag Pharma GmbH & Co. KG |
Friday

13:00 – 13:30 Diabetic Polyneuropathy – What’s new in multimodal management? Dan Ziegler (GER) Wörwag Pharma GmbH & Co. KG 6 October 2023 13:00 –

Legal notice | Data protection

Manage Cookie Consent

We use cookies to optimize our website and service.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Vorlieben Vorlieben

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Show settings

{title} {title} {title}

Category: Wörwag Pharma GmbH & Co. KG

Diabetic Polyneuropathy – What’s new in multimodal management? Wörwag Pharma GmbH & Co. KG | Friday

Diabetic Polyneuropathy – What’s new in multimodal management?

Wörwag Pharma GmbH & Co. KG |
Friday